- Home
- CADL vs GEVO Comparison
CADL vs GEVO Comparison
Compare CADL & GEVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CADL
- GEVO
- Stock Information
- Founded
- CADL 1999
- GEVO 2005
- Country
- CADL United States
- GEVO United States
- Employees
- CADL N/A
- GEVO N/A
- Industry
- CADL Biotechnology: Pharmaceutical Preparations
- GEVO Major Chemicals
- Sector
- CADL Health Care
- GEVO Industrials
- Exchange
- CADL Nasdaq
- GEVO Nasdaq
- Market Cap
- CADL 234.8M
- GEVO 246.8M
- IPO Year
- CADL 2021
- GEVO 2011
- Fundamental
- Price
- CADL $5.45
- GEVO $1.26
- Analyst Decision
- CADL Strong Buy
- GEVO Buy
- Analyst Count
- CADL 4
- GEVO 2
- Target Price
- CADL $21.00
- GEVO $7.58
- AVG Volume (30 Days)
- CADL 991.5K
- GEVO 3.5M
- Earning Date
- CADL 05-13-2025
- GEVO 05-13-2025
- Dividend Yield
- CADL N/A
- GEVO N/A
- EPS Growth
- CADL N/A
- GEVO N/A
- EPS
- CADL N/A
- GEVO N/A
- Revenue
- CADL N/A
- GEVO $42,034,000.00
- Revenue This Year
- CADL N/A
- GEVO $631.78
- Revenue Next Year
- CADL N/A
- GEVO $80.71
- P/E Ratio
- CADL N/A
- GEVO N/A
- Revenue Growth
- CADL N/A
- GEVO 145.38
- 52 Week Low
- CADL $3.79
- GEVO $0.48
- 52 Week High
- CADL $14.60
- GEVO $3.39
- Technical
- Relative Strength Index (RSI)
- CADL 50.27
- GEVO 65.60
- Support Level
- CADL $5.18
- GEVO $1.00
- Resistance Level
- CADL $6.29
- GEVO $1.39
- Average True Range (ATR)
- CADL 0.41
- GEVO 0.08
- MACD
- CADL 0.08
- GEVO 0.02
- Stochastic Oscillator
- CADL 42.89
- GEVO 87.22
About CADL Candel Therapeutics Inc.
Candel Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing viral immunotherapies to help patients fight cancer. The company has established two clinical-stage viral immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) constructs, respectively.
About GEVO Gevo Inc.
Gevo Inc is a renewable chemicals and biofuels company engaged in the development and commercialization of alternatives to petroleum-based products based on isobutanol produced from renewable feedstocks. The operating segments are the Gevo segment, GevoFuels segment, and the GevoRNG segment. By its segments, it is involved in research and development activities related to the future production of SAF, commercial opportunities for other renewable hydrocarbon products and isobutanol, including the development of its biocatalysts, and the produces-pipeline quality methane gas captured from dairy cow manure. The company derives maximum revenue from the GevoRNG segment.